Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this NIH study, female donor to male recipient sex mismatch was significantly associated with the development of vitiligo and/or alopecia areata in patients with chronic graft-vs-host disease.

This study reported a significant relapse in alopecia areata among patients infected with COVID-19, possibly due to the infection's inflammatory response and stress from quarantine.

This study found that the Alopecia Areata Patient Priority Outcomes questionnaire is a reliable and valid tool for measuring the severity and impact of hair loss in individuals with alopecia areata.

In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.

A kidney transplant patient on cyclosporin experienced unexpected severe hair loss, which improved with treatment adjustments.

This study found compelling genetic evidence linking atopic and allergic conditions with the development of alopecia areata, suggesting a need for closer monitoring in affected individuals.

This study reviews the epidemiology of alopecia areata in the UK, focusing on its links to mental health comorbidities, autoimmune/atopic associations, and common infection incidences.

This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.

This paper introduces an algorithm for using smart device-mounted microscopes to analyze scalp images and diagnose hair loss by extracting specific hair loss features.

This study found that trichoscopy is essential for evaluating the severity of alopecia areata and predicting treatment responses, contributing to more personalized patient management.

This review of real-world treatment options for AA indicates that current therapies are insufficient, with high dissatisfaction rates, highlighting a need for improved solutions.

This study demonstrated that the Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata cases with high sensitivity and specificity in a dermatology clinic setting.

This study developed a new neural network model (AA-GAN-AB-MTEDeep) to enhance Alopecia Areata classification using synthetic scalp images, achieving an accuracy of 96.94%.

This case report describes a patient with autoimmune polyglandular syndrome type 3 who experienced total hair regrowth following the successful control of diabetes with insulin therapy.

This study found that baricitinib improved symptoms of atopic dermatitis and alopecia areata in both adults and children in real-world settings, aligning with clinical trial results, while noting low discontinuation due to adverse events and no new safety concerns.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

This study established consensus criteria for classifying alopecia areata severity, aiding clinicians in accurate diagnosis and treatment planning.

This study analyzed gene expression data to identify key genes involved in severe forms of alopecia areata, discovering four immune monitoring genes (LGR5, SHISA2, HOXC13, S100A3) with potential for early diagnosis and better understanding of the disease's biological mechanisms.

This review discusses the classification, diagnosis, and potential treatment pathways for Alopecia Areata, emphasizing the complex genetic and immunological factors involved, but reports no new clinical results.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

This study observed that patients with alopecia areata had significantly lower serum 25-hydroxyvitamin D levels than healthy controls, with a trend toward even lower levels in more severe cases.

In this study, researchers used Mendelian randomization to find a significant genetic association between rheumatoid arthritis and an increased risk of alopecia areata, suggesting RA patients should be vigilant for potential AA development.

This study conducted in Europe found that both physicians and patients generally agreed on the severity of alopecia areata, with higher physician-rated severity linked to increased patient-reported burdens such as anxiety, depression, and work impairment.

This study reported that alopecia areata mostly affects young Black African males, with very few associated pathologies observed in this population.

In this study, researchers developed a predictive model for the onset of alopecia areata by analyzing six datasets to identify key feature genes and employing various machine learning algorithms, ultimately finding the XGBoost model most effective for clinical application.

This study indicates that the EQ-5D-5L may not effectively capture the burden of alopecia areata on patients' health-related quality of life, and suggests that alternative measures might better assess treatment benefits related to hair regrowth.

This article discusses the perspectives of clinicians and patients on alopecia areata, an autoimmune disorder with significant psychosocial impacts, highlighting the unpredictability and limited effectiveness of current treatments as well as the key unmet needs and gaps in care.

This genome-wide association study identified several genetic markers, including specific SNPs and HLA genotypes, associated with alopecia areata susceptibility in the Taiwanese population, highlighting key pathways involved in immune response and offering insights into the genetic origins of this autoimmune condition.

In this study, Canadian patients with alopecia areata and their caregivers reported a significant negative impact on their quality of life, including high feelings of self-consciousness, anxiety, and risk of adjustment disorder.